News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CHMP Recommends Otsuka Pharmaceutical Co., Ltd.'s Deltyba™ (Delamanid) For EU Approval For Treatment Of Multidrug-Resistant Tuberculosis (MDR-TB) In Combination With Optimized Background Regimen (OBR)



11/25/2013 6:59:58 AM




comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES